A glycoprotein binding complement component C3d was isolated from media used for culture of Raji human lymphoblastoid cells. Analysis by sodium dodecyl sulfate/polyacrylamide gel electrophoresis and ...

One of the challenges faced when developing influenza virus vaccines is the problem of how to protect populations in the face of spreading pandemics. With the advent of air travel, this readily ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

The classical pathway is activated by C1q-mediated recognition of the target. Further activation of this pathway causes C4b and its cleavage product iC4b to accumulate in the tissues. C4b binds to C2 ...

A team of investigators at the Medical University of South Carolina (MUSC) has developed a novel therapy for ischemic (clot-caused) stroke and has shown in a preclinical model that it locally inhibits ...

Scientists develop novel “complement inhibitor” therapy that reduces brain tissue inflammation and nerve cell damage following stroke with better recovery of neurological deficits. Currently tissue ...